Arbutus Biopharma (ABUS) Tax Provisions (2015 - 2022)

Arbutus Biopharma (ABUS) has reported Tax Provisions for 6 consecutive years, with $4.4 million the latest figure, recorded in Q1 2022.

• Quarterly Tax Provisions changed N/A year-over-year to $4.4 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $4.4 million (changed N/A YoY) and the FY2022 annual result came in at $4.4 million, changed N/A from the prior year.
• Tax Provisions improved to $4.4 million in Q1 2022 per ABUS's latest filing, from -$12.7 million in the prior quarter.
• Over the last five years, Tax Provisions for ABUS reached as high as $4.4 million in Q1 2022 and fell as low as -$12.7 million in Q3 2019.
• A 3-year average of -$4.2 million and a median of -$4.3 million in 2018 frame the typical range for Tax Provisions.
• The largest YoY upside for Tax Provisions was 195.56% in 2019 against a maximum downside of 195.56% in 2019.
• Year by year, Tax Provisions stood at -$4.3 million in 2018, then slumped by 195.56% to -$12.7 million in 2019, then soared by 135.11% to $4.4 million in 2022.
• According to Business Quant data, Tax Provisions over the past three periods registered $4.4 million, -$12.7 million, and -$4.3 million for Q1 2022, Q3 2019, and Q3 2018 respectively.